MedPAC To Examine Hospitals’ Handling Costs For Outpatient Drugs
This article was originally published in The Pink Sheet Daily
Study will examine whether changes are needed to the outpatient prospective payment system. The Medicare Payment Advisory Commission also will investigate how comparative and cost-effectiveness data are used by payers other than Medicare.
You may also be interested in...
The anti-emetic would be covered by Medicare Part B when used in combination with a 5-HT3 antagonist and dexamethasone in patients refractory to standard treatments, CMS says. Other uses of Emend would be covered under Part D beginning in 2006.
FDA asks Endo to disseminate “corrective messages” to doctors who received the violative promotional materials, which the agency says omit risk information and contain unsubstantiated effectiveness claims.
Studies that look for differences in efficacy among members of the same drug class are only performed when necessary for approval, CDER Office of Medical Policy Director Temple tells DIA. While questioning the introduction of "follow-on" compounds, Temple also highlights AstraZeneca's success in achieving a more optimal dose for Nexium.